Quantitative and qualitative changes in platelet traits of sunitinib-treated patients with renal cell carcinoma in relation to circulating sunitinib levels: a proof-of-concept study

BACKGROUND: Tyrosine kinase inhibitors (TKIs), such as sunitinib, are used for cancer treatment, but may also affect platelet count and function with possible hemostatic consequences. Here, we investigated whether patient treatment with the TKI sunitinib affected quantitative and qualitative platele...

Descripción completa

Detalles Bibliográficos
Autores principales: Tullemans, Bibian M. E., Brouns, Sanne L. N., Swieringa, Frauke, Sabrkhany, Siamack, van den Berkmortel, Franchette W. P. J., Peters, Natascha A. J. B., de Bruijn, Peter, Koolen, Stijn L. W., Heemskerk, Johan W. M., Aarts, Maureen J. B., Kuijpers, Marijke J. E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9195440/
https://www.ncbi.nlm.nih.gov/pubmed/35698081
http://dx.doi.org/10.1186/s12885-022-09676-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9195440/
https://www.ncbi.nlm.nih.gov/pubmed/35698081
http://dx.doi.org/10.1186/s12885-022-09676-0

Ejemplares similares